Date: 2017-07-17
Type of
information: Results
phase: preclinical
Announcement: results
Company: Sutro Biopharma (USA - CA)
Product: STRO-001
Action
mechanism: antibody drug conjugate. STRO-001 is an antibody drug conjugate (ADC) targeting the CD74 cell surface protein in hematologic B-cell malignancies.
Disease: non-Hodgkin lymphoma, multiple myeloma
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On July 17, 2017, Sutro Biopharma announced that STRO-001, an antibody drug conjugate targeting the CD74 cell surface protein in hematologic B-cell malignancies, has been shown to eradicate tumors in human xenograft models of non-Hodgkin lymphoma and multiple myeloma – diseases that Sutro plans to evaluate for treatment in a Phase I clinical trial planned for early 2018.
- The research findings, which come as Sutro prepares to file an investigational new drug application to begin the clinical testing, show that STRO-001 eliminated tumors or significantly delayed tumor growth in diffuse large B-cell lymphoma and mantle cell lymphoma xenograft models and prolonged survival in the disseminated Mino mantle cell lymphoma xenograft model compared to tumor models treated with vehicle, which developed advanced disease with palpable neck and abdominal tumors.
- STRO-001 also suppressed tumor growth in a diffuse large B-cell lymphoma tumor model, SU-DHL-6, when administered with standard of care chemotherapy.
- In immunohistochemistry testing using the unconjugated antibody component of STRO-001 with a large number of human lymphoma tissue samples, researchers also confirmed that CD74 is highly-expressed in diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
- Sutro presented the findings on June 14-16 in Lugano, Switzerland at the 14th International Conference on Malignant Lymphoma, and on June 23 in Madrid at the 22nd Congress of the European Hematology Association.
- Additionally, research on STRO-001 revealed potent antitumor activity in multiple myeloma xenograft models and potent in vitro cytotoxicity in multiple non-Hodgkin lymphoma cell lines.
- Bioluminescence imaging with the luciferase MM.1S xenograft model showed that a single dose of the Sutro ADC eradicated multiple myeloma at each post-treatment time point investigated, compared to animals treated with vehicle, which experienced diffuse replacement of bone marrow with malignant myeloma. The imaging enabled researchers to quantify tumor growth in response to treatment and vehicle more precisely than in earlier xenograft tumor models designed to assess survival. Sutro presented the findings on June 23 in Madrid at the 22nd Congress of the European Hematology Association.
Is
general: Yes
